Gilead surges wild­ly as world scram­bles to counter a like­ly coro­n­avirus pan­dem­ic while GSK pitch­es in on vac­cine R&D cam­paign

Gilead shares soared af­ter sug­gest­ing that one of its an­tivi­rals could help counter the rapid­ly spread­ing Wuhan coro­n­avirus, which has now in­fect­ed thou­sands of peo­ple in Chi­na and killed more than 300.

The biotech an­nounced late Fri­day that it’s work­ing with Chi­nese au­thor­i­ties to start a ran­dom­ized con­trolled tri­al to test remde­sivir, the drug they at­tempt­ed but ul­ti­mate­ly failed to push for ebo­la, as a treat­ment for 2019-nCoV. The news trig­gered a 12% spike for the stock $GILD pre-mar­ket — a fre­net­ic gain for a com­pa­ny with a mar­ket cap near $80 bil­lion that comes just as as US health of­fi­cials con­firmed the like­li­hood of a glob­al pan­dem­ic.

As a glob­al R&D ef­fort to whip up a fast vac­cine — which Glax­o­SmithK­line has just joined — grows, some drug­mak­ers (and in­vestors) are hop­ing a ther­a­peu­tic, es­pe­cial­ly one that’s been de­ployed in hu­mans be­fore, could pro­vide faster re­lief and reap huge prof­its.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER